Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease
Investigational Oral Candidate JOTROL™ Addresses a Parkinson’s Disease Market with No Current Disease-modifying Therapies Available Jupiter Neurosciences, Inc. (NASDAQ:JUNS) JUPITER, FL, UNITED STATES, May 27, 2026 /EINPresswire.com/ -- Jupiter …